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Abstract
Background—Trichomonas vaginalis is the most prevalent nonviral sexually transmitted 
infection in the United States, affecting 3.1% of women of reproductive age. Infection is 
associated with HIV acquisition and pelvic inflammatory disease. In the United States, Centers for 
Disease Control and Prevention guidelines recommend testing all women with vaginal discharge 
for T. vaginalis, but except for HIV-infected women, there are no national guidelines for screening 
asymptomatic persons. The objective of this analysis is to assess testing and screening practices 
for T. vaginalis among symptomatic and asymptomatic women in the sexually transmitted disease 
(STD) clinic setting.
Methods—We analyzed data on demographics, clinical presentation, and laboratory testing for 
all women visiting a clinician in 2010 to 2011 at any of 15 STD clinics participating in the STD 
Surveillance Network. Prevalence of laboratory-confirmed T. vaginalis infection was calculated 
among symptomatic women tested and among asymptomatic women screened.
Results—A total of 59,176 women visited STD clinicians: 39,979 were considered symptomatic 
and 19,197 were considered asymptomatic for T. vaginalis infection, whereas 211 were HIV-
infected. Diagnostic practices varied by jurisdiction: 4.0% to 96.1% of women were tested or 
screened for T. vaginalis using any laboratory test. Among 17,952 symptomatic women tested, 
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prevalence was 26.2%. Among 3909 asymptomatic women screened, prevalence was 6.5%. 
Among 92 HIV-infected women tested/screened, prevalence was 29.3%.
Conclusions—Trichomoniasis is common among STD clinic patients. In this analysis, most 
STD clinics tested symptomatic women seeking care, in accordance with national guidelines. All 
HIV-infected women should be screened annually. Additional evidence and national guidance are 
needed regarding potential benefits of T. vaginalis screening in other asymptomatic women.
Trichomonas vaginalis is the most prevalent curable sexually transmitted infection in the 
world.1 In the United States, according to the 2000 to 2004 National Health and Nutrition 
Examination Survey, an estimated 3.1% of women of reproductive age are infected with T. 
vaginalis, making this parasitic infection more prevalent than either chlamydia or 
gonorrhea.2,3 A disproportionately high burden of disease has been observed among older 
women and non-Hispanic black women.2,4 Infection with T. vaginalis has been associated 
with serious adverse outcomes such as pelvic inflammatory disease5,6 and 1.5 to 2.7 times 
greater risks of HIV acquisition and transmission.7–10
An estimated 70% to 85% of infected women are asymptomatic.2,11 Symptoms of 
trichomoniasis range from mild to severe inflammation and genital pruritis and may also 
include cervicovaginal and/or urethral discharge. A single oral dose of a nitroimidazole 
antimicrobial (ie, 2 g of metronidazole or tinidazole) is generally sufficient treatment to cure 
infection.12 Although in vitro antimicrobial resistance has been documented in 4% of 
vaginal culture specimens collected from sexually transmitted disease (STD) clinics, in vivo 
antimicrobial resistance has remained infrequent to date.13,14
The Centers for Disease Control and Prevention (CDC) STD Treatment Guidelines 
recommend that all women seeking care for symptoms of vaginal discharge should be tested 
for T. vaginalis infection.12 As for screening asymptomatic persons, however, these 
guidelines recommend routine annual screening only among HIV-infected women and 
currently do not include specific recommendations for T. vaginalis screening among the 
general population or among other high-risk groups.12 Although approximately 71% of male 
sexual partners of women with trichomoniasis are also infected with T. vaginalis, clinical 
testing for this parasite is not commonly conducted for male patients.15
Traditional diagnostic testing is by wet mount microscopy, in which a specimen of genital 
(eg, cervicovaginal) fluid is collected by a clinician during a pelvic examination and 
interpreted at the point of care; the test is inexpensive but operator dependent, and sensitivity 
is generally poor at 51% to 65%.16,17 Additional testing options include culture, which does 
not provide immediate results and is less commonly performed; recently developed rapid 
antigen tests, which may be performed at the point of care; and nucleic acid amplification 
tests (NAATs), the first of which was cleared for use in symptomatic or asymptomatic 
women by the US Food and Drug Administration in 2011, with high sensitivity (95%–
100%) and specificity (95%–100%) for detecting T. vaginalis in urine specimens, 
endocervical swabs, or vaginal swabs.16,18,19
Little is known about current diagnostic testing and screening practices for this very 
common STD among persons presumably at high risk for infection, such as patients 
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presenting at STD clinics.20 The objective of this analysis was to assess T. vaginalis 
prevalence among symptomatic and asymptomatic women tested or screened at a diverse 
group of STD clinics in the United States.
MATERIALS AND METHODS
Demographic, clinical, and laboratory data were collected from all patients visiting 
geographically diverse, publicly funded, urban STD clinics participating in the STD 
Surveillance Network (SSuN). Established by the CDC in 2005, SSuN is a sentinel 
surveillance system comprising collaborating state and local health departments that follow 
similar protocols for collecting and analyzing enhanced STD surveillance data. The purpose 
of SSuN is to improve the capacity of national, state, and local STD programs to detect, 
monitor, and respond rapidly to trends in STDs.21 SSuN data collection is a public health 
surveillance activity. Analysis of de-identified SSuN data does not constitute research 
involving human subjects, so institutional review board review was not required.
We analyzed data on demographics, clinical presentation including signs and symptoms of 
trichomoniasis, and laboratory testing for T. vaginalis among all women visiting a clinician 
at each of 15 participating STD clinics from January 1, 2010, through December 31, 2011.
These 15 STD clinics were located in 6 states: Alabama (1 clinic), California (1 clinic), 
Colorado (1 clinic), New York (9 clinics), Pennsylvania (2 clinics), and Washington (1 
clinic). Jurisdictions were included if at least 1 STD clinic site routinely collected clinical 
data on signs and symptoms of trichomoniasis as well as laboratory test results for T. 
vaginalis. Women were included if they had at least 1 clinician visit because T. vaginalis 
testing could be performed only by clinicians at these clinics; women were excluded if their 
only visit types were express or rapid visits in which T. vaginalis testing could not have been 
performed.
Patient characteristics (eg, demographics) were collected during any one of multiple visits 
and summed across all visits. Age was defined as age at the latest clinician visit. HIV 
infection was determined by at least 1 positive laboratory test result for HIV and/or self-
report of HIV infection at any visit during the analytic period. A nonspecific symptom of 
trichomoniasis was a subjective report of vaginal discharge, odor, or itching; a nonspecific 
sign of trichomoniasis was an objective finding of vaginal discharge observed during 
physical examination by a clinician. For this analysis, women were classified as 
“symptomatic” if they had any relevant subjective symptom and/or objective sign, and as 
“asymptomatic” if no relevant symptom or sign was reported. Among women receiving a 
diagnostic test for T. vaginalis, symptomatic women were considered to have received 
testing, whereas asymptomatic women were considered to have received screening. Women 
were considered to have T. vaginalis infection only if they had a positive result on any type 
of laboratory test (ie, wet mount, culture, NAAT, or any other type of test) for T. vaginalis 
infection at a participating STD clinic within the analytic time frame; clinical diagnoses 
made by the clinician were not considered. Jurisdictions also provided local information 
regarding their current clinic policies and procedures regarding testing and screening for T. 
vaginalis.
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Descriptive statistics were calculated using SAS (version 9.2, SAS Institute, Cary, NC). 
Testing and screening practices for T. vaginalis were assessed by jurisdiction of the 
participating STD clinics. Prevalence of laboratory-confirmed infection detected was 
calculated both among symptomatic women tested and among asymptomatic women 
screened for T. vaginalis infection. In addition, testing and screening practices were assessed 
for the subgroup of women who were known to be HIV-infected.
RESULTS
A total of 233,101 people, including 90,432 women, visited 1 of the 15 participating STD 
clinics at least once in 2010 to 2011; excluding express visits and other nonclinician visit 
types, 59,176 women made at least 1 visit to an STD clinician. Demographic characteristics 
of these women visiting STD clinicians are summarized both overall and by jurisdiction in 
Table 1. The largest proportion of women was in the 20- to 29-year age group both overall 
(52.2%) and also within each jurisdiction (range, 48.0%–54.3%). As for race/ethnicity, 
overall the largest proportion of women identified as non-Hispanic black (55.6%), but this 
proportion varied between jurisdictions (range, 21.0%–85.9%).
Among the 59,176 women visiting clinicians at STD clinics, 39,979 had signs or symptoms 
that could be consistent with trichomoniasis (67.6%; range, 38.4%–87.3% between 
jurisdictions), and the other 19,197 women did not have signs or symptoms of 
trichomoniasis (32.4%; range, 12.7%–61.6% between jurisdictions). A total of 211 women 
were known to be HIV-infected. Testing and screening practices among symptomatic, 
asymptomatic, and HIV-infected women are described in Table 2.
Among the 39,979 symptomatic women, 17,952 (44.9% overall; range, 5.3%–98.7%) were 
tested for T. vaginalis infection; however, at least 89.3% of symptomatic women were tested 
in all jurisdictions except one (New York), where only 5.3% of symptomatic women were 
tested. Of symptomatic women tested for T. vaginalis, 4700 (26.2% overall; range, 8.4%–
50.1%) were found to be infected.
Among the 19,197 women without signs or symptoms, 3909 (20.4% overall; range, 1.6%–
84.8%) were screened for T. vaginalis infection. After excluding the New York jurisdiction, 
where 1.6% of asymptomatic women were screened, screening practices still varied 
considerably by jurisdiction (52.5% overall; range, 20.9%–84.8%). Of asymptomatic 
women who were screened, 254 (6.5% overall; range, 1.6%–15.0%) were found to be 
infected with T. vaginalis.
Our population included 211 women known to be HIV-infected. Of these, only 92 (43.6% 
overall; range, 5.5%–100%) were tested or screened for T. vaginalis infection at the 
participating STD clinics; these practices varied considerably by jurisdiction, with only 1 
clinic reporting that 100% of HIV-infected women were screened at least once during the 2-
year period. Among these 211 HIV-infected women, 121 (57.3%) had symptoms or signs 
consistent with trichomoniasis, whereas 90 (42.7%) were asymptomatic. Testing and 
screening rates were low in both subgroups: among the 121 symptomatic HIV-infected 
women, 56 (46.3%) were tested, and among the 90 asymptomatic HIV-infected women, 36 
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(40.0%) were screened. T. vaginalis infection was confirmed in 27 HIV-infected women, 
corresponding to 29.3% of those who were tested or screened.
There were 4954 women with at least 1 positive laboratory test result for T. vaginalis during 
this period. Wet mount was the laboratory method used almost exclusively at all sites; 
culture was used rarely, and no clinic reported using rapid antigen testing or NAAT testing 
for T. vaginalis during this period.
The prevalence of infection among women tested or screened for T. vaginalis in the STD 
clinic setting is summarized by age and race/ethnicity in Figure 1. Among symptomatic 
women who were tested, the prevalence of laboratory-confirmed trichomoniasis increased in 
a stepwise fashion with increasing age, from 22.8% in women 19 years or younger, up to 
33.7% in women 50 years or older. Prevalence was higher among non-Hispanic black 
women tested, ranging from 29.9% in black women 19 years or younger up to 40.3% in 
black women 50 years or older. Among asymptomatic women screened, the prevalence of T. 
vaginalis infection was 6.5% overall, without much variation by age. Prevalence was higher 
among non-Hispanic black women screened than among non-Hispanic white or Hispanic 
women screened. These observed disparities are consistent with previously published 
population-based reports on the epidemiology of T. vaginalis infections.2
Clinics reported several notable differences in their policies and procedures with respect to 
testing and screening for T. vaginalis. At STD clinics in some states, clinicians both collect 
and interpret wet mounts, whereas in others, microscopy is performed only by laboratory 
personnel. At the clinics in Alabama and Pennsylvania, screening is routinely performed for 
all women receiving a pelvic examination regardless of symptoms, a practice that exceeds 
CDC recommendations. (In 2012, NAAT testing for T. vaginalis was implemented at the 
STD clinic in Alabama.) At the clinics in Colorado, California, and Washington, wet mount 
testing is generally performed only for symptomatic women who receive a pelvic 
examination, consistent with CDC recommendations. However, at the New York clinics, 
owing to financial restrictions, the diagnosis of trichomoniasis is made on clinical grounds,* 
and wet mount is performed only on women for whom a clinical diagnosis is in doubt or in 
the event of treatment failure.
DISCUSSION
In this analysis of 59,176 women visiting STD clinicians at 15 STD clinics, clinics in most 
jurisdictions tested symptomatic women for trichomoniasis, in accordance with national 
guidelines, yet screening practices varied widely. Consistent with CDC recommendations, at 
least 89% of symptomatic women were tested for T. vaginalis in all jurisdictions—except 
the largest one, New York, where budget limitations have nearly eliminated wet mount 
testing from STD clinics. Among symptomatic women visiting an STD clinician and 
receiving a laboratory test for T. vaginalis, the prevalence of infection was high at 26.2%. 
Even among asymptomatic women screened, prevalence of T. vaginalis was 6.5%, more 
*Laboratory tests for trichomoniasis were reported from all 9 New York clinics in both 2010 and 2011; 1 of these clinics reported that 
additional wet mount testing was conducted for a special project during the first 3 quarters of 2010 and did not reflect usual clinic 
practice.
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than double the 3.1% prevalence estimated for US women overall. In Alabama, where 
nearly universal testing was conducted, detected prevalence was particularly high, for 
reasons that are only partly understood. Differences between jurisdictions in demographic 
characteristics including race may play an important role. In addition, given the low 
sensitivity of wet mount testing used in all jurisdictions, some additional cases may have 
been missed. These results are concerning in light of previously published smaller studies 
that have reported that T. vaginalis prevalence may be 13% to 15% among women at STD 
clinics.22,23
Screening practices for T. vaginalis among asymptomatic women varied widely between 
jurisdictions. Differences in local testing policies may have contributed to vastly different 
testing rates: for example, some clinics had instituted T. vaginalis screening for all women 
receiving a pelvic examination. We observed that STD clinics performing more screening 
tests detected a higher prevalence of T. vaginalis infections (an unusual pattern because 
increasing screening often leads to a reduction in observed disease prevalence rates, even as 
the number of detected cases increases). This lack of consistent practices might be addressed 
by implementing national screening guidelines for T. vaginalis among asymptomatic 
women. Routine screening regardless of symptomatic status may be worthwhile in 
populations with a high prevalence of infection and where treatment can prevent adverse 
outcomes.
Given the national recommendation that all HIV-infected women should be screened for T. 
vaginalis infection upon entry to care and at least annually thereafter, regardless of 
symptoms,12 the finding that only 43.6% of HIV-infected women were tested or screened 
over a 2-year period, after visiting STD clinicians in an STD clinic setting, revealed a 
probable room for improvement in most jurisdictions. Clinicians should assess and 
document whether HIV-infected women have been screened for trichomoniasis within the 
past year and should offer this recommended service if needed.
This analysis is subject to several important limitations. First, patients at these 15 STD 
clinics may not be representative of all US STD clinics or other broader segments of the 
population. Although most patients were seen in a jurisdiction where diagnostic testing for 
T. vaginalis was rarely performed (New York), positivity rates among women who were 
tested and screened in this jurisdiction were comparable with other sites. Second, any 
trichomoniasis testing or screening that these patients may have received in other practice 
settings beyond the STD clinic, such as primary care clinics, could not be assessed. Third, 
cultures for T. vaginalis performed at some sites during 2010 were for a research project and 
did not reflect usual clinic practice, although the small number of culture tests performed 
had little impact on the results of this analysis. In addition, adequacy of treatment provided 
could not be assessed for any patients or their sexual partners; because treatment data are not 
reported in SSuN, patients at some sites may have received appropriate empiric treatment 
based on clinical presentation alone, whether or not a positive laboratory test result for T. 
vaginalis was documented.
Historically, public health resources for STDs have focused on nationally notifiable 
diseases, including chlamydia, gonorrhea, syphilis, and HIV infection.3,24 Despite the high 
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prevalence of infection, observed health disparities, and communicability of infection, 
trichomoniasis is not currently a reportable disease in any state, nor is it a nationally 
notifiable condition, largely because of a lack of consistent evidence for severity of disease, 
associated costs, preventability of adverse outcomes, or perceived public interest.25 
Prevalence estimates commonly used to derive cost-effectiveness thresholds for other STDs 
are as low as a population prevalence of 3% for chlamydia26 or 0.1% for HIV,27 above 
which screening asymptomatic persons has been recommended to minimize sequelae. 
Further research is needed to clarify whether T. vaginalis infection causes sequelae even if 
asymptomatic, and to determine the cost-effectiveness and affordability of expanded 
screening. Additional evidence would be helpful to clarify when T. vaginalis screening 
should be recommended for asymptomatic individuals at high risk, such as STD clinic 
patients.
Where microscopy is not available or desirable, providers may want to assess the net 
benefits of introducing highly sensitive NAATs or other same-day tests as options for 
expediting T. vaginalis screening, either alone or as part of an algorithm when wet mount 
testing is negative.17 However, the feasibility of expanding use of these technologies under 
funding constraints is unclear. Nationally, a key criterion for recommending screening is the 
ability to intervene successfully to reduce poor health outcomes. Nitroimidazole 
antimicrobials are a simple, effective, inexpensive, and widely available treatment for T. 
vaginalis infection, yet they are the only drug class available, and the potential development 
of antimicrobial-resistant parasites is an ominous prospect.12,28 Also, several studies have 
found that treating T. vaginalis infection reduces genital shedding of HIV RNA,29–31 yet it 
has not been demonstrated that the successful treatment of trichomoniasis reduces the risk of 
HIV transmission. Furthermore, health consequences of asymptomatic T. vaginalis 
infections remain poorly defined. Although trichomoniasis has been identified as an 
independent risk factor for pelvic inflammatory disease and HIV infection, women visiting 
clinicians in the STD clinic setting may have additional risk factors for these serious adverse 
events.5,6 Future research may clarify the role T. vaginalis infection plays in the ongoing 
HIV epidemic, especially among racial/ethnic minority populations in the United States. 
Answers to such questions might provide evidence to support revisions of national screening 
recommendations.
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Figure 1. 
Prevalence of infection among women tested or screened for T. vaginalis in the STD clinic 
setting, by age group and race/ethnicity among symptomatic women tested (A) and among 
asymptomatic women screened (B)—6 states (15 STD clinics), 2010 to 2011.
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